Their results concluded that inflammasome-independent NLRP3 is involved in mitochondrial ROS production and renal tubular cell injury secondary to hypoxemia, suggesting that inflammasome-independent NLRP3 could be considered as a therapeutic target to prevent the progression of renal disease to a chronic state [52]. Here, NLRP3 is linked to kidney disorder.